This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Amdoxovir

Cocrystal Pharma, Inc.

Drug Names(s): DAPD, AMDX

Description: Amdoxovir is a guanosine nucleoside analogue. It is a prodrug that is deaminated by adenosine deaminase to its 2’-deoxyguanosine analog, DXG ((-)-[beta]-D-dioxolane guanine). The triphosphate form of DXG is a selective inhibitor of HIV-1 reverse transcriptase and also acts as a viral DNA chain terminator.

Deal Structure: Triangle and Emory and University of Georgia
In March 1996, Triangle Pharmaceuticals, Inc. entered into a licensing agreement with Emory University and the University of Georgia Research Foundation for worldwide rights to amdoxovir.

Emory and University of Georgia and Shire
Under the terms of a settlement announced in September 2002, Emory University and the University of Georgia Research Foundation received an exclusive license to Shire Pharmaceuticals' patent rights covering amdoxovir. Emory University and the University of Georgia Research Foundation granted Triangle an exclusive sublicense to these rights. In exchange, Triangle will pay Shire Pharmaceuticals a royalty on future amdoxovir sales.

Gilead and Triangle
In December 2003, Gilead announced its acquisition of Triangle Pharmaceuticals.

Gilead and Emory and University of Georgia
In January 2004, Gilead ended its licensing agreement with Emory University and...See full deal structure in Biomedtracker

Partners: Shire Pharmaceuticals Group PLC


Amdoxovir News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug